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AbstrACt
Objectives We compared long-term outcomes in 
patients with atrial fibrillation (AF) with and without a 
secondary precipitant.
Design and setting Retrospective cohort study based 
on Danish nationwide registries.
Participants Patients with AF with and without 
secondary precipitants (1996–2015) were matched 
1:1 according to age, sex, calendar year, CHA2DS2-
VASc score and oral anticoagulation therapy (OAC), 
resulting in a cohort of 39 723 patients with AF with 
a secondary precipitant and the same number of 
patients with AF without a secondary precipitant. 
Secondary precipitants included alcohol intoxication, 
thyrotoxicosis, myocardial infarction, surgery and 
infection in conjunction with AF.
Primary and secondary outcomes The primary 
outcome in this study was thromboembolic events. 
Secondary outcomes included AF rehospitalisation and 
death. Long-term risks of outcomes were examined by 
multivariable Cox regression analysis.
results The most common precipitants were infection 
(55.0%), surgery (13.2%) and myocardial infarction 
(12.0%). The 5-year absolute risk of thromboembolic 
events (taking death into account as a competing risk) 
in patients with AF grouped according to secondary 
precipitants were 8.3% (alcohol intoxication), 8.5% 
(thyrotoxicosis), 12.1% (myocardial infarction), 11.6% 
(surgery), 12.2% (infection), 10.1% (>1 precipitant) 
and 12.3% (no secondary precipitant). In the 
multivariable analyses, AF with a secondary precipitant 
was associated with the same or an even higher 
thromboembolic risk than AF without a secondary 
precipitant. One exception was patients with AF and 
thyrotoxicosis: those not initiated on OAC therapy carried 
a lower thromboembolic risk the first year of follow-up 
than matched patients with AF without a secondary 
precipitant and no OAC therapy.
Conclusions In general, AF with a secondary precipitant 
was associated with the same thromboembolic risk as 
AF without a secondary precipitant. Consequently, this 
study highlights the need for more research regarding 
the long-term management of patients with AF 
associated with a secondary precipitant.
IntrODuCtIOn
The aetiology of atrial fibrillation (AF) 
remains partly unknown. Studies have shown 
that an inflammatory reaction inside the atria 
always precipitate AF.1 However, in clinical 
practice, AF may occur as an isolated event 
or together with a secondary precipitant. AF 
is associated with a fivefold increased risk of 
ischaemic stroke, and detailed treatment strat-
egies regarding stroke prophylaxis in patients 
with AF occurring without secondary precip-
itants exist in both European and American 
treatment guidelines.2–5 In contrast, there is 
no consensus regarding stroke prophylaxis in 
patients with AF occurring with a secondary 
precipitant. Previous guidelines stated that 
AF occurring secondary to another precip-
itant usually will terminate without recur-
rence.2 In current guidelines, however, this 
statement has been omitted, and the need 
for data regarding AF associated with a 
secondary precipitant highlighted.4 5 Studies 
investigating long-term outcomes in AF asso-
ciated with a secondary precipitant are sparse 
and data differentiating between different 
secondary precipitants and taking oral anti-
coagulation (OAC) therapy into account are 
missing.
strengths and limitations of this study
 ► The study was based on high-quality nationwide 
registries with many years of follow-up.
 ► Complete follow-up was possible.
 ► Only associations could be drawn because of the 
retrospective and non-randomised design.
 ► Atrial fibrillation with and without a secondary 
precipitant was defined from diagnosis codes at 
discharge.
 ► We had no data on ECGs at discharge.
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Figure 1 Patient selection. AF, atrial fibrillation.
To address this lack in current knowledge, we aimed to 
compare long-term outcomes including thromboembolic 
events, AF rehospitalisation and death in patients with AF 
with a secondary precipitant (including alcohol, intox-
ication, thyrotoxicosis, myocardial infarction, surgery 
and infection) and patients with AF without a secondary 
precipitant. Further, we were able to differentiate between 
patients receiving and not receiving stroke prophylaxis 
with OAC therapy.
MAterIAls AnD MethODs
Data sources
In Denmark, healthcare is tax financed and with equal 
availability regardless of socioeconomic status. Date of 
birth, date and cause of death, emigration and immigra-
tion status, diagnosis and surgery codes, and so on, from 
all hospital contacts fulfilled prescriptions of medicine, and 
several other parameters are registered in different nation-
wide registries. Since all Danish citizens are provided a 
unique personal identifier code at birth (or immigration), 
data from the registries can be crosslinked on an individual 
level. We linked data from the following registries: The 
Danish Civil Registration System,6 The Danish National 
Patient Registry (diagnoses were registered in terms of 
the International Classification of Diseases (ICD) system 
(ICD-8 until 1994 and in terms of ICD-10 thereafter)),7 
The Danish Register of Causes of Death8 and the Danish 
National Registry of Medicinal Statistics (medicines were 
registered according to the Anatomical Therapeutic Chem-
ical classification system (ATC)).9
study population
The patient selection is depicted in figure 1. We included 
all Danes diagnosed and admitted to a Danish hospital 
with AF for the first time between 1996 and 2015. 
Patients<18 years or >100 years and those with valvular AF 
(defined as AF without: rheumatic valve disease of aortic 
valve or mitral valve or prosthetic heart valve (any valve)) 
were excluded. Since there was a possibility that some of 
the patients had been diagnosed with AF at their general 
practitioner before their hospital admission, we excluded 
those who previously had fulfilled a prescription of anti-
arrhythmic therapy or rate-controlling drugs (including 
amiodarone, flecainide and digoxin) and those who had 
fulfilled a prescription of OAC therapy up to 100 days 
before their hospital admission. Further, patients who 
died or had a thromboembolic event during the hospital 
admission or a constructed blanking period of 4 weeks 
from hospital discharge to the index date were excluded.
Patients were grouped in those with and without a 
secondary precipitant. Patients who had a diagnosis of 
one of the following precipitants from their AF hospital 
admission were defined as patients with a secondary 
precipitant: alcohol intoxication, thyrotoxicosis, myocar-
dial infarction and infection. Also, patients who were 
diagnosed with AF after, but during the same hospital 
admission they received surgery, were defined as having 
AF with a secondary precipitant. We restricted the popu-
lation of patients with AF without a secondary precipitant 
to patients with AF without a diagnosis of a secondary 
precipitant from their hospital admission. Patients 
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with AF with and without a secondary precipitant were 
matched 1:1 by incidence density sampling according to 
age (allowing a difference of up to 2 years), sex, calendar 
year (allowing a difference up to 2 years), CHA2DS2-VASc 
group (0, 1–2, >2) and OAC therapy status at the index 
date. Consequently, each case was matched with a control 
diagnosed at the same time and in the same age with AF. 
Further, the control had the same sex and was catego-
rised in the same CHA2DS2-VASc group as the case. These 
patients comprised the study population. We used a previ-
ously described function to perform the match.10
long-term outcomes
The index date was defined 4 weeks from AF hospital 
discharge. Initiation of OAC therapy and antiarrhythmic 
and rate controlling drugs was assessed during this 
blanking period from discharge to index date. Patients 
were followed from the index date and until the first event 
of the following: an outcome of interest, death, 5 years 
from the index date, emigration or 30 June 2015. The 
primary outcome of interest was thromboembolic events (a 
composite of ischaemic stroke, transient ischaemic attack 
and systemic thrombosis or embolism) while secondary 
outcomes included AF rehospitalisation and all-cause death. 
AF rehospitalisation was defined as a hospitalisation with AF 
as the primary discharge diagnosis. The diagnoses of AF, 
ischaemic stroke and myocardial infarction have been vali-
dated in the Danish registries with positive predictive values 
of 93%, 97% and 100%, respectively.11 12
statistics
Kaplan-Meier curves for death were drawn and cumula-
tive incidences of thromboembolic events (with incorpo-
rated competing risk of death) calculated using the Aalen 
Johansen estimator. The log-rank test and Grey’s test were 
used to test for differences in the cumulative incidence 
of long-term outcomes. Cox regression analyses were 
performed to calculate HRs of long-term outcomes in 
patients with AF with and without a secondary precipitant 
according to OAC therapy at the index date. All analyses 
were performed on the matched population. The multivar-
iate models were adjusted for other potential confounders 
than the matching criteria (including comorbidities at 
the index date (including peripheral artery disease, heart 
failure, hypertension, prior thromboembolic event, isch-
aemic heart disease, chronic kidney disease, diabetes, prior 
bleeding event, cancer) and antiarrhythmic and rate-con-
trolling therapy during the blanking period (amiodarone, 
digoxin, flecainide)). The analyses took matching variables 
into account and each group of patients with AF with a 
secondary precipitant was compared with its respective 
matches from the matching procedure. The models were 
tested for the assumption of proportional hazards. For 
specification of diagnosis codes and ATC codes, see online 
supplementary table 1. A p<0.05 was considered statistically 
significant. All statistical analyses were performed in SAS 
statistical software V.9.4 or R.13
Other analyses
Analyses of long-term outcomes were also performed on 
a non-matched population including all patients available 
before the matching (figure 1). To account for changes in 
OAC therapy status over time, we did a sensitivity analysis 
not stratifying patients with regard to their OAC therapy 
status at the index date, but instead adjusting for OAC 
therapy status as a time-dependent variable. Consequently, 
new initiations and discontinuations were taking into 
account. The method used has been used and described 
previously.14–16
Patient and public involvement
This was a retrospective study based on administrative 
registries. Patients and the public were not involved in 
the development of the study.
results
study population
As shown in figure 1, the most common secondary precip-
itant was infection (21 824 patients, 55.0%). Further, 
335 (0.8%) patients had a concurrent alcohol intoxica-
tion, 2507 (6.3%) had thyrotoxicosis, 4773 (12.0%) had 
acute myocardial infarction, 5229 (13.2%) had under-
went surgery and 5055 (12.7%) had >1 precipitant. Of 
those with >1 precipitant, 4788 (94.7%) patients had two 
secondary precipitants, while 267 (5.3%) had three or 
four secondary precipitants. Infection and surgery were 
the most common combination of secondary precipi-
tants. The patients with >1 precipitant were grouped in 
one group, and were not included in the other groups 
of patients with AF with a secondary precipitant. During 
the blanking period, 14% of the patients with AF and a 
secondary precipitant and 2% of the patients with AF 
without a secondary precipitant died, while 5% and 2%, 
respectively, had a thromboembolic event. These patients 
were excluded before the matching.
baseline characteristics
Baseline characteristics of the matched study popula-
tion are shown in table 1. In general, patients with AF 
with a secondary precipitant had more comorbidities 
than patients with AF without a secondary precipitant. 
Baseline characteristics of the non-matched population 
according to OAC therapy at the index date are shown 
in online supplementary tables 2 and 3. Especially, those 
with AF and myocardial infarction, surgery, infection 
and >1 precipitant were older, had more comorbidities, 
and higher risk scores for stroke and bleeding compared 
with patients with AF without a secondary precipitant. 
Among the patients with AF with a secondary precipitant 
(non-matched study population), 9.9% with alcohol intox-
ication, 43.9% with thyrotoxicosis, 27.2% with myocardial 
infarction, 21.9% with surgery, 27.1% with infection and 
21.4% with >1 precipitant received OAC therapy at the 
index date, respectively. Among patients with AF without 
a secondary precipitant, 38.5% received OAC therapy 
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Figure 2 Number of events, incidence rates, and crude and adjusted HRs of long-term outcomes in patients with atrial 
fibrillation (AF) with and without a secondary precipitant. OAC, oral anticoagulation.
at the index date. In general, for patients with AF with 
and without a secondary precipitant, those initiated on 
OAC therapy suffered from less cancer, chronic kidney 
disease, peripheral artery disease, and had fewer previous 
bleeding events than those not initiated on OAC therapy. 
On the other hand, they were more likely to suffer from 
stroke risk factors (including diabetes, heart failure, 
ischaemic heart disease and hypertension) than those 
not initiated on OAC therapy. During the first year after 
the index date, 9.9% and 17.3% of patients with AF with 
and without a secondary precipitant, respectively, had a 
new hospital admission with AF. One year after the index 
date, 19.8% and 32.7% of the patients with AF with and 
without a secondary precipitant, respectively, were in 
OAC therapy and 22.3% and 21.8% of the patients with 
AF with and without a secondary precipitant, respectively, 
were in antiarrhythmic therapy.
long-term outcomes
Number of events, incidence rates and crude and adjusted 
HRs of thromboembolic events and death in patients with 
AF with a secondary precipitant compared with patients 
with AF without a secondary precipitant initiated and not 
initiated on OAC therapy at the index date are presented in 
figure 2. With few exceptions, AF with a secondary precipi-
tant was associated with the same thromboembolic risk as AF 
without a secondary precipitant. Regardless of OAC therapy 
status at the index date, AF with infection was associated 
with a significantly increased risk of thromboembolic events 
compared with AF without a secondary precipitant. Among 
those not initiated on OAC therapy, AF with thyrotoxicosis 
was associated with a significantly lower risk of thromboem-
bolic events compared with AF without a secondary precip-
itant. In those initiated on OAC therapy, no differences 
in thromboembolic risk were observed between patients 
with AF and thyrotoxicosis and patients with AF without a 
secondary precipitant. All subgroups of AF with a secondary 
precipitant were associated with a significantly lower risk of 
AF rehospitalisation compared with AF without a secondary 
precipitant (figure 2).
Figures 3 and 4 depict cumulative incidences of throm-
boembolic events and death in patients with AF with and 
without a secondary precipitant. During follow-up, the 
cumulative incidence of thromboembolic events (taking 
death as an competing risk into account) according to 
the type of secondary precipitant was 8.3% (alcohol 
intoxication), 8.5% (thyrotoxicosis), 12.1% (myocardial 
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Figure 3 Cumulative incidence of thromboembolic (TE) events outcomes by secondary precipitant and oral anticoagulation 
(OAC) therapy at the index date. AF, atrial fibrillation.
Figure 4 Cumulative incidence of death events outcomes by secondary precipitant and oral anticoagulation (OAC) therapy at 
the index date. AF, atrial fibrillation.
infarction), 11.6% (surgery), 12.2% (infection), 10.1% 
(>1 precipitant) and 12.3% (no secondary precipitant). 
The cumulative incidence of AF rehospitalisation was 
19.6% (alcohol intoxication), 30.8% (thyrotoxicosis), 
27.2% (myocardial infarction), 14.8% (surgery), 20.9% 
(infection), 19.3% (>1 precipitant) and 34.4% (no 
secondary precipitant) (not included in the figures).
OAC therapy initiation compared with no OAC therapy 
initiation was associated with a lower thromboembolic 
risk in patients with AF with and without a secondary 
precipitant, although the results did not reach statistical 
significance in patients with AF with alcohol intoxica-
tion, thyrotoxicosis, myocardial infarction and surgery as 
secondary precipitants (figure 5).
Other analyses
The long-term risk of thromboembolic events for patients 
with AF with and without a secondary precipitant in the 
non-matched population was comparable to the risks 
found in the main analysis, except that AF with thyrotox-
icosis reached statistical significance and hence was asso-
ciated with a significantly lower risk of thromboembolic 
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Figure 5 Adjusted HRs of long-term outcomes in patients with atrial fibrillation (AF) initiated versus not initiated on oral 
anticoagulation (OAC) therapy (stratified according to type of AF).
events (HR 0.75, 95% CI 0.60 to 0.95 for those initiated 
on OAC therapy and HR 0.77, 95% CI 0.64 to 0.92 for 
those not initiated on OAC therapy). Further, among 
those initiated on OAC therapy, AF after surgery was asso-
ciated with an increased risk of thromboembolic events 
(HR 1.23, 95% CI 1.01 to 1.50).
The sensitivity analysis, adjusting for OAC therapy status 
as a time-dependent variable, revealed results similar to 
those found in the main analysis (online supplementary 
figure 1).
DIsCussIOn
We examined long-term outcomes in patients with AF 
with and without a secondary precipitant. The study 
had two main findings: first, AF with different secondary 
precipitants was in general associated with the same 
thromboembolic risk as AF without a secondary precip-
itant. Second, OAC initiation rates differed significantly 
according to type of secondary precipitant. Further, OAC 
therapy versus no OAC therapy was associated with a 
lower thromboembolic risk in those with AF and infec-
tion and >1 precipitant while no significant risk reduction 
was seen for patients with AF with the other secondary 
precipitants.
thromboembolic risk
Despite lower rehospitalisation rates with AF, AF with a 
secondary precipitant was in general associated with the 
same thromboembolic risk as AF without a secondary 
precipitant. AF with thyrotoxicosis was associated with a 
lower thromboembolic risk compared with AF without 
a secondary precipitant. In contrast, AF with infection 
was associated with an increased thromboembolic risk 
compared with AF without a secondary precipitant. 
This is in accordance with previous findings.17–19 In two 
previous studies, Lubitz et al and Fauchier et al exam-
ined long-term outcomes in patients with AF secondary 
to a reversible precipitant compared with patients with 
AF without a secondary precipitant. In both studies, AF 
secondary to a reversible precipitant was associated with 
the same thromboembolic risk as AF without secondary 
precipitants. However, both studies were smaller and with 
patients included before 2012 and 2010, respectively.20 21 
In summary, our results together with previous studies 
suggest that AF with a secondary precipitant in general, 
and maybe with the exception of AF with thyrotoxicosis, 
may be considered as similar to AF without a secondary 
precipitant with respect to thromboembolic risk.
OAC therapy
OAC therapy showed a tendency towards a lower throm-
boembolic risk in patients with AF and a secondary 
precipitant, but did only reach statistical significance 
for patients with AF and infection and >1 precipitant. 
Recently, Quon et al examined risk of thromboembolic 
events and bleeding in patients with AF and acute coro-
nary syndrome, acute pulmonary disease and infection 
according to OAC therapy status after discharge. In that 
study, OAC therapy was not associated with a lower risk 
of thromboembolic events in patients with AF and the 
before-mentioned precipitants. However, the analyses 
on long-term outcomes were based on logistic regression 
analysis, and did therefore not include survival time in the 
model. Since patients with AF with a secondary precip-
itant in our study seemed to die at a higher rate than 
patients with AF without a secondary precipitant, the time 
perspective is crucial when studying long-term outcomes 
in this setting.22 Studies with a clinical randomised design 
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would be able to show whether patients with AF with a 
secondary precipitant benefit from OAC therapy on 
the same terms as patients with AF without a secondary 
precipitant.
OAC treatment rates
The non-matched population allowed us to describe 
trends in OAC therapy initiation in patients with AF 
with and without a secondary precipitant. In patients 
with AF without a secondary precipitant, 38.5% of the 
patients were initiated on OAC therapy at the index date. 
This is in accordance with previous findings, taking into 
account that our study period went back to 1996 when 
treatment rates were lower than today.23 24 In 2017, 
Chean et al assessed current practice of AF among criti-
cally ill patients with new-onset AF. The study was based 
on questionnaires answered by members of the Intensive 
Care Society in UK. The results revealed that 63.8% of 
the respondents would not regularly anticoagulate criti-
cally ill patients with new-onset AF. We found important 
differences in OAC therapy initiation rates in patients 
with AF with a secondary precipitant according to the 
type of precipitant. Patients with alcohol intoxication had 
the lowest initiation rate of OAC therapy (9.9%). Almost 
50% of this patient group had a CHA2DS2-VASc score 
of 0 and hence no indication for OAC therapy. Further 
patients with alcohol abuse may have poor compliance 
and increased bleeding risk.25 Consequently, there may 
be caution among physicians in prescribing OACs for this 
patient group. In 2011, Traube and colleagues reviewed 
the literature with respect to thromboembolic risk in 
patients with AF and thyrotoxicosis. They concluded that 
OAC therapy should be initiated for those patients who 
did not have any contraindications for treatment.26 This 
could explain the high OAC treatment initiation rates in 
this patient group (43.9%).
limitations
First of all, this study was a retrospective registry-based 
study and hence no causative relationships can be drawn. 
Our definition of AF with a secondary precipitant was 
based on diagnosis codes from hospital admissions with 
AF and a reversible precipitant. Both diagnoses were regis-
tered at the discharge date, and therefore we may have 
included patients in the group of AF with a secondary 
precipitant who developed AF before the secondary 
precipitant (eg, patients admitted with AF who devel-
oped infection during their hospital stay), and thereby 
should have been classified as patients with AF without 
a secondary precipitant. Moreover, we had no access to 
patient files, and we did not know the duration of AF or 
whether the patients were discharged in sinus rhythm or 
with AF. Also, no data were available with regard to the 
physicians’ considerations when choosing between OAC 
therapy and no OAC therapy, patients compliance and 
measurements of international normalised ratio and time 
in therapeutic range for warfarin users.
The retrospective, registry-based nature of this study 
also precluded consideration of the specific impact of the 
molecular causes of both acute and chronic AF, including 
inflammatory activation and impaired nitric oxide (NO) 
availability and signalling. For example, specific patterns 
and extent of inflammatory activation associated with 
intercurrent infection could not be determined, and 
while impaired NO antiaggregatory effect occurs in acute 
AF27 and increased plasma concentrations of asymmetric 
dimethylarginine, which inhibits enzymatic generation 
of NO, predict thromboembolic risk in AF,28 neither of 
these parameters were measured in the current study. 
However, this study was based on a nationwide cohort 
of patients with many years of follow-up and data from 
high-quality registries. It reveals unexpected results that 
should be considered in future treatment guidelines for 
patients with AF and a secondary precipitant.
Conclusion
In this study, we found that patients with AF and a 
secondary precipitant carried a similar associated throm-
boembolic risk as those with AF without a secondary 
precipitant. Current guidelines lack data on this subject 
and our results suggest that AF in relation to known trig-
gers may be considered as AF in general.
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